Amgen Slide and Narrow Breadth Drag Health Care Lower

The Health Care sector closed -2.6% on Tuesday, September 8, with selling spreading across the group even though 52.1% of the fund's graded weight sits in companies with an A or B quality grade. Breadth was severely restricted, with just 5.4% of the sector's S&P 500 members advancing. The Health Care Select Sector SPDR Fund, an exchange-traded fund managing $43.9 billion under the ticker XLV, closed -2.5% at $167.16. The downturn was led by Amgen Inc (-10.1%), while modest gains from Universal Health Services Inc (+1.4%) and UnitedHealth Group Incorporated (+0.9%) did little to stem the retreat.

The sector-wide slide followed clinical pipeline setbacks and corporate warnings that triggered widespread selling. Amgen dropped sharply after a competitor's Phase 3 clinical trial failure clouded the outlook for its rival cardiovascular therapy, which overshadowed its own positive lung cancer trial results and prompted an analyst downgrade. The broader medical space took an additional hit after a major medical device maker warned that a recent cyberattack would hurt its 2026 sales and profit. Losses deepened across the industry as several large pharmaceutical and device names declined together on a day when 2 of the 11 sectors rose.

The cap-weighted sector move of -2.6% matched the equal-weighted return of -2.5% closely, showing that selling pressure was distributed across companies of all sizes rather than isolated to a few large holdings. The single-session decline follows extended strength, with XLV standing at +0.9% over the past month, +14.0% over the past one hundred sessions, and +21.3% over the past twelve months.

EasyAlpha grades each company against its industry peers. Companies graded A or B have stronger fundamentals, and historically they have carried a lower risk of large drawdowns than companies graded D or E. Within the sector, 52.1% of the fund's graded weight sits in companies with an A or B grade.